181 related articles for article (PubMed ID: 37008582)
41. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
[TBL] [Abstract][Full Text] [Related]
42. Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis.
Zhao YJ; Khoo AL; Tan G; Teng M; Tee C; Tan BH; Ong B; Lim BP; Chai LY
Antimicrob Agents Chemother; 2016 Jan; 60(1):376-86. PubMed ID: 26525782
[TBL] [Abstract][Full Text] [Related]
43. Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison.
Tormo M; Pérez-Martínez A; Calabuig M; Hernández-Boluda JC; Amat P; Navarro D; Solano C
Mycoses; 2018 Mar; 61(3):206-212. PubMed ID: 29125660
[TBL] [Abstract][Full Text] [Related]
44. Clinical experience with posaconazole prophylaxis--a retrospective analysis in a haematological unit.
Hahn J; Stifel F; Reichle A; Holler E; Andreesen R
Mycoses; 2011 Jan; 54 Suppl 1():12-6. PubMed ID: 21126267
[TBL] [Abstract][Full Text] [Related]
45. Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey.
Pagano L; Verga L; Busca A; Martino B; Mitra ME; Fanci R; Ballanti S; Picardi M; Castagnola C; Cattaneo C; Nadali G; Nosari A; Candoni A; Caira M; Salutari P; Lessi F; Aversa F; Tumbarello M
J Antimicrob Chemother; 2014 Nov; 69(11):3142-7. PubMed ID: 24948702
[TBL] [Abstract][Full Text] [Related]
46. Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis.
Kaya Z; Gursel T; Kocak U; Aral YZ; Kalkanci A; Albayrak M
Pediatr Blood Cancer; 2009 Apr; 52(4):470-5. PubMed ID: 19058205
[TBL] [Abstract][Full Text] [Related]
47. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
Ullmann AJ; Lipton JH; Vesole DH; Chandrasekar P; Langston A; Tarantolo SR; Greinix H; Morais de Azevedo W; Reddy V; Boparai N; Pedicone L; Patino H; Durrant S
N Engl J Med; 2007 Jan; 356(4):335-47. PubMed ID: 17251530
[TBL] [Abstract][Full Text] [Related]
48. Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections.
Furuno JP; Tallman GB; Noble BN; Bubalo JS; Forrest GN; Lewis JS; Bienvenida AF; Holmes CA; Weber BR; McGregor JC
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012757
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease.
O'Sullivan AK; Weinstein MC; Pandya A; Thompson D; Langston AA; Perfect JR; Papadopoulos G
Am J Health Syst Pharm; 2012 Jan; 69(2):149-56. PubMed ID: 22215361
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States.
O'Sullivan AK; Pandya A; Papadopoulos G; Thompson D; Langston A; Perfect J; Weinstein MC
Value Health; 2009; 12(5):666-73. PubMed ID: 19508661
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry.
Pagano L; Caira M; Candoni A; Aversa F; Castagnola C; Caramatti C; Cattaneo C; Delia M; De Paolis MR; Di Blasi R; Di Caprio L; Fanci R; Garzia M; Martino B; Melillo L; Mitra ME; Nadali G; Nosari A; Picardi M; Potenza L; Salutari P; Trecarichi EM; Tumbarello M; Verga L; Vianelli N; Busca A;
Clin Infect Dis; 2012 Dec; 55(11):1515-21. PubMed ID: 22955439
[TBL] [Abstract][Full Text] [Related]
52. Assessing the impact of prophylactic anidulafungin during remission induction of acute myeloid leukemia - A propensity-score matching analysis.
Silva WFD; Mendes FR; Melo RDCB; Velloso EDRP; Rocha V; Rego EM
J Mycol Med; 2023 Nov; 33(4):101434. PubMed ID: 37683564
[TBL] [Abstract][Full Text] [Related]
53. Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections.
Cattaneo C; Panzali A; Passi A; Borlenghi E; Lamorgese C; Petullà M; Re A; Caimi L; Rossi G
Mycoses; 2015 Jun; 58(6):362-7. PubMed ID: 25907298
[TBL] [Abstract][Full Text] [Related]
54. Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands.
Jansen JP; O'Sullivan AK; Lugtenburg E; Span LF; Janssen JJ; Stam WB
Ann Hematol; 2010 Sep; 89(9):919-26. PubMed ID: 20383504
[TBL] [Abstract][Full Text] [Related]
55. Invasive fungal infections in pediatric patients with hematologic malignancies receiving oral amphotericin B solution and early intravenous administration of fluconazole.
Watanabe N; Matsumoto K; Kojima S; Kato K
J Pediatr Hematol Oncol; 2011 May; 33(4):270-5. PubMed ID: 21464763
[TBL] [Abstract][Full Text] [Related]
56. Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial.
Fisher BT; Zaoutis T; Dvorak CC; Nieder M; Zerr D; Wingard JR; Callahan C; Villaluna D; Chen L; Dang H; Esbenshade AJ; Alexander S; Wiley JM; Sung L
JAMA; 2019 Nov; 322(17):1673-1681. PubMed ID: 31688884
[TBL] [Abstract][Full Text] [Related]
57. [Economic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndrome].
Lazzaro C
Infez Med; 2010 Jun; 18(2):91-103. PubMed ID: 20610931
[TBL] [Abstract][Full Text] [Related]
58. [Breakthrough of invasive fungal disease with posaconazole as primary prophylaxis after induction chemotherapy for acute myeloid leukemia].
Pei RZ; Lu Y; Zhang PS; Liu XH; Chen D; Du XH; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Tang SH
Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):213-217. PubMed ID: 32146748
[No Abstract] [Full Text] [Related]
59. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
[TBL] [Abstract][Full Text] [Related]
60. Low Rate of Invasive Fungal Infections During Induction and Consolidation Chemotherapy for Adults with De Novo Acute Myeloid Leukemia Without Anti-mold Prophylaxis: Single-Center 2002-2018 Empirical/Pre-emptive Approach.
Martino R; Garrido A; Santaliestra M; García-Cadenas I; Novelli S; Saavedra SD; Esquirol A; Granell M; Briones J; Moreno C; Brunet S; Giménez A; Hidalgo A; Sánchez F; Sierra J
Mycopathologia; 2020 Aug; 185(4):639-652. PubMed ID: 32564177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
